RESP 4230-Unit III Review

COPD/Asthma

100

Dyspnea can be best described as:

a. obvious breathing difficulty.

b. always commensurate with degree of lung function.

c. primarily physiological.

d. having physiological, affective, and sensory components.

d. having physiological, affective, and sensory components.

200

The GOLD report states that COPD results from a mixture of risk factors and genetics.

True or False

True

300

The use of tiotropium for stable COPD significantly reduces hospitalizations for exacerbation.

True or False

True

400

Which of the following characteristics justify the use of antibiotics for an exacerbation? (SELECT ALL THAT APPLY)

I.    Purulent sputum

II.    Nonproductive cough

III.    Mechanical ventilation

IV.    Increase in sputum volume

V.    Refractory dyspnea

VI.    Increase in shortness of breath

I, III, IV, VI

500

Which GOLD patient group has a low exacerbation risk with significant symptoms?

a. Group B

b. Group D

c. Both group A and group D

d. Group C

b. Group D

COPD/Asthma II

100

The primary focus of asthma management is:

a.    providing affordable medications.

b.    determining the severity of asthma.

c.    control.

d.    reducing ICS dosage

c.    control.

200

A clinician focuses therapy for the patient with COPD with the main goal of:

A. increasing reimbursement for the acute care facility.

B. prescribing affordable medications.

C. reducing hospital length of stay.

D. preventing another exacerbation.

D. preventing another exacerbation.

300

A patient has been diagnosed with severe persistent asthma. The clinical features include: (SELECT ALL THAT APPLY)

I.    nocturnal symptoms twice per month and PEF 60–80% of predicted.

II.    daily symptoms.

III.    exacerbation affecting sleep and activity.

IV.    frequent exacerbations and limitation of physical activities.

V.    frequent nocturnal asthma symptoms and brief exacerbations.

II, IV

400

Which severity classification is characterized by daily use of SABA?

a.    Severe persistent

b.    Intermittent

c.    Mild persistent

d.    Moderate persistent

d.    Moderate persistent

500

Which of the following are tools that can describe patient symptomology? (SELECT ALL THAT APPLY)

I. FEV1 and FVC

II. Number of exacerbations in last 12 months

III. CAT

IV. MMRC and FVC

V. CAT and FEV1

VI. CAT and FEV1/FVC ratio

VII. MMRC

III & VII

Bronchiectasis

100

Bronchiectasis is characterized by all BUT which of these symptoms?

a.    Wheezes

b.    Frequent cough

c.    Scant secretions

d.    Respiratory infections

c.    Scant secretions

200

To focus bronchiectasis therapy, the clinician should:

a.    identify the most therapeutic ICS for the patient.

b.    prescribe the most affordable ACT.

c.    identify the etiology of the disease.

d.    perform serial HRCT studies.

c.    identify the etiology of the disease.

300

Which of the following are NOT components for bronchiectasis therapy?

a.    Inhaled corticosteroids

b.    Bronchodilators

c.    Antitussives

d.    Inhaled antibiotics

c.    Antitussives

400

Which class of medication has, in addition to its primary property, both anti-inflammatory and immunomodulatory effects?

a.    Macrolide

b.    Mucolytic

c.    Bronchodilator

d.    Corticosteroid

a.    Macrolide

500

Which of the following are pathologic processes that are present in bronchiectasis? (SELECT ALL THAT APPLY)

I.    Intact mucociliary blanket

II.    Structural lung damage and airflow obstruction

III.    Failure of mucus clearance and bacterial colonization

IV.    Diaphragmatic instability

V.    Airway inflammation

VI.    Bacterial colonization and impaired cough

II, III, V

Interstitial Lung Disease / Pulmonary Hypertension

100

Common presenting symptoms of ILD include:

a.    nonproductive cough.

b.    rhonchi.

c.    inspiratory wheeze.

d.    weight gain.

a.    nonproductive cough.

200

ILDs that are neoplastic in origin include all but which of the following disorders?

a.    Lymphangioleiomyomatosis

b.    Bronchoalveolar carcinoma

c.    Leukemia

d.    Hodgkin disease

a.    Lymphangioleiomyomatosis

300

PAH is present when:

a.    mean pulmonary artery pressure is greater than 20 mm Hg.

b.    PCWP is greater than 15 mm Hg.

c.    mean pulmonary artery pressure is greater than 25 mm Hg.

d.    PCWP is greater than 20 mm Hg.

c.    mean pulmonary artery pressure is greater than 25 mm Hg.

400

Which two PH groups have targeted therapy?

a.    1 and 4

b.    2 and 4

c.    3 and 5

d.    4 and 5

a.    1 and 4

500

Diagnostic criteria for AE-IPF does not include:

a.    HCRT findings.

b.    previous diagnosis.

c.    spirometry.

d.    infection.

c.    spirometry.